DSIP (5 mg Vial) Dosage Protocol

Plan based on an 8–12 week daily protocol with gradual titration.

• Peptide Vials (DSIP, 5 mg each):
  • 8 weeks at ~200 mcg/day avg ≈ 2–3 vials
  • 12 weeks at ~200 mcg/day avg ≈ 3–4 vials
  • 12 weeks at ~300 mcg/day avg ≈ 5–6 vials
• Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 3 vials: 9 mL - 1 bottle required (10 mL each)
  • 5 vials: 15 mL - 2 bottles required (10 mL each)
  • 6 vials: 18 mL - 2 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs - 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs - 2 boxes required (100 swabs each)

DSIP 5 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
• Typical daily range: 100–300 mcg once daily (gradual titration); advanced up to 500 mcg.
• Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

DSIP - delta sleep-inducing peptide - is a naturally occurring nine-amino-acid research peptide studied in older human and preclinical work involving sleep architecture, sleep timing, and stress-related physiology^[1][3][6]. The human literature is small, older, and often based on intravenous administration, so it does not validate the subcutaneous schedule displayed on this page^[2][5]. This protocol keeps the vial calculations separate from those evidence limits.

The 5 mg vial is reconstituted with 3.0 mL for an approximate concentration of 1.67 mg/mL. At that concentration, one U-100 syringe unit equals 0.01 mL, or approximately 16.7 mcg of DSIP. The dosage range, timing, and progression remain exactly as displayed in the chart above.

• Compound: DSIP (delta sleep-inducing peptide)
• Vial strength: 5 mg
• Final volume: 3.0 mL
• Concentration: approximately 1.67 mg/mL
• U-100 conversion: 1 unit = 0.01 mL ≈ 16.7 mcg

The concentration follows directly from dividing 5 mg by the 3.0 mL final volume. A 100 mcg amount is about 6 U-100 units (0.06 mL), 250 mcg is about 15 units (0.15 mL), and 500 mcg is about 30 units (0.30 mL). These are arithmetic conversions for the schedule already displayed, not independent dosing recommendations.

The supplier-linked bottle listing identifies the DSIP vial as a 5 mg strength used for these calculations^[14]. For other vial strengths or reconstitution volumes, use the peptide dosage and reconstitution calculator rather than carrying over these syringe markings.

DSIP stands for delta sleep-inducing peptide, a naturally occurring nonapeptide first characterized in early experimental work on sleep-related neurophysiology^[1]. DSIP is a neuropeptide used in research, not an established sleep medication. Reviews discuss possible roles in sleep regulation, endocrine signaling, and responses to stress while emphasizing the limits of the evidence^[6][10].

Research on DSIP has examined effects on sleep, including sleep onset, sleep timing, sleep efficiency, REM sleep, deep sleep, slow-wave sleep, delta sleep, and subjective sleep quality^[3][5]. The findings were not uniform. These terms describe outcomes measured or discussed in early studies; they do not establish benefits of DSIP, natural sleep enhancement, improved sleep quality, or restorative sleep.

Preclinical experiments also reported sleep-related effects at low doses, but animal results cannot establish a human DSIP dosage protocol^[7]. The current evidence does not show that DSIP reliably regulates the sleep cycle in a general population.

Published human research is limited to small studies from earlier decades, and some experiments used intravenous delivery rather than subcutaneous injection^[2][3][5]. Those studies provide research context for DSIP and sleep architecture, but they do not validate the schedule or vial calculations on this page.

DSIP is not FDA-approved and is not approved by the FDA for a clinical use. No established clinical dosage range, standardized safety profile, or confirmed treatment role has been defined. It should not be presented as equivalent to approved sleep medications.

Preclinical studies have explored DSIP in models of stress protection and oxidative stress^[4][11]. These findings support investigation of stress hormones, cellular defense, sleep and recovery, and rest and recovery pathways, but they are not proof of a therapeutic effect in humans or evidence that DSIP can regulate sleep.

Protein and peptide stability depends on formulation, temperature, moisture, light exposure, and handling^[8][9]. Follow the storage directions shown in the four reconstitution checks above and the product’s lot-specific documentation. Keep the reconstituted vial refrigerated at 2–8 °C (36–46 °F), protect it from light, and avoid unnecessary agitation or repeated warming.

Because controlled modern human data are sparse, adverse-effect frequency, interaction risks, and long-term safety remain uncertain. DSIP may be discussed online as a sleep aid, but a favorable outcome in an early study or animal model is not evidence that DSIP is safe, well tolerated, or effective for insomnia.

This page is an educational calculation resource. It does not diagnose sleep disorders, replace professional medical evaluation, or recommend DSIP for human use.

U-100 syringe units are volume markings: 100 units equals 1 mL. They are not peptide international units. General subcutaneous-administration references describe site selection, skin preparation, and injection angle, but they do not validate the administration of DSIP or the schedule on this page^[12][13].

What concentration results from adding 3 mL to a 5 mg vial?

The final concentration is approximately 1.67 mg/mL.

How much DSIP is in one U-100 syringe unit?

At 1.67 mg/mL, one unit (0.01 mL) contains approximately 16.7 mcg.

Does the 5 mg vial strength change the research schedule?

Vial strength changes concentration, vial yield, and syringe-unit calculations. The schedule on this page remains the one displayed in the dosage chart.

What does the research say about DSIP for sleep?

Older small studies examined sleep timing and sleep architecture, but the evidence is inconsistent and insufficient to establish an approved treatment protocol.

Is DSIP FDA-approved?

No. DSIP is not an FDA-approved medication, and its clinical safety and effectiveness have not been established.

This DSIP 5 mg dosage protocol is provided for educational and research-reference purposes only. The displayed schedule has been preserved, while the surrounding discussion distinguishes arithmetic vial conversions from the limited evidence base.

• 1
  
  Schoenenberger GA, Monnier M (1977)
  - Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA

  View Source
• 2
  
  European Journal of Anaesthesiology (2001)
  - Delta sleep-inducing peptide: editorial review of mechanisms and clinical context

  View Source
• 3
  
  Schneider-Helmert D, Schoenenberger GA (1983)
  - Effects of DSIP in man: multifunctional psychophysiological properties. Neuropsychobiology

  View Source
• 4
  
  Sudakov KV et al. (2004)
  - Delta-sleep-inducing peptide sequelae: stress protective effect. Ann N Y Acad Sci

  View Source
• 5
  
  Schneider-Helmert D (1981)
  - Acute and delayed effects of DSIP on human sleep behavior. Int J Clin Pharmacol Ther Toxicol

  View Source
• 6
  
  Graf MV, Kastin AJ (1984)
  - Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev

  View Source
• 7
  
  Iyer KS et al. (1988)
  - Sleep-inducing effect of low doses of DSIP in rats. Indian J Exp Biol

  View Source
• 8
  
  Manning MC et al. (2010)
  - Stability of protein pharmaceuticals: an update. Pharm Res

  View Source
• 9
  
  Wang W (2000)
  - Lyophilization and development of solid protein pharmaceuticals. Int J Pharm

  View Source
• 10
  
  Yehuda S, Carasso RL (1988)
  - DSIP: brain mechanisms and function. Int J Neurosci

  View Source
• 11
  
  Khvatova EM et al. (2003)
  - Delta sleep-inducing peptide: effect on oxidative stress in brain during different models. Biull Eksp Biol Med

  View Source
• 12
  
  CDC
  - Vaccine administration: subcutaneous route (angle/site; no aspiration)

  View Source
• 13
  
  NCBI Bookshelf
  - Medication Administration: Subcutaneous Injections (Open RN Nursing Skills)

  View Source
• 14
  
  Pure Lab Peptides
  - DSIP (5 mg) product page (quality and batch documentation)

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.